Compare PSO & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PSO | ABVX |
|---|---|---|
| Founded | 1844 | 2013 |
| Country | United Kingdom | France |
| Employees | N/A | N/A |
| Industry | Books | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.9B | 9.2B |
| IPO Year | 2000 | N/A |
| Metric | PSO | ABVX |
|---|---|---|
| Price | $13.16 | $123.02 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 11 |
| Target Price | N/A | ★ $130.09 |
| AVG Volume (30 Days) | 814.6K | ★ 1.8M |
| Earning Date | 02-27-2026 | 08-11-2025 |
| Dividend Yield | ★ 2.48% | N/A |
| EPS Growth | ★ 31.65 | N/A |
| EPS | ★ 0.90 | N/A |
| Revenue | ★ $4,822,578,436.00 | $6,231,374.00 |
| Revenue This Year | $2.36 | $6.80 |
| Revenue Next Year | $5.20 | N/A |
| P/E Ratio | $13.82 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $12.42 | $4.77 |
| 52 Week High | $17.90 | $148.83 |
| Indicator | PSO | ABVX |
|---|---|---|
| Relative Strength Index (RSI) | 43.01 | 50.83 |
| Support Level | $12.42 | $113.64 |
| Resistance Level | $14.84 | $122.50 |
| Average True Range (ATR) | 0.25 | 8.45 |
| MACD | -0.13 | -0.57 |
| Stochastic Oscillator | 29.96 | 58.34 |
UK-listed Pearson is a testing and educational provider. Pearson's primary operations are in assessment and qualification testing and higher education, but they also provide English education and testing, virtual learning, prehiring testing and screening, and upskilling/reskilling. The company divested noncore businesses, including the Financial Times, The Economist, and publishing house Penguin, and is now focused on being an educational resource and testing provider.
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.